Stiripentol is a third-generation antiepileptic compound. It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits. It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices. Stiripentol (500 μM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5. Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.
Stiripentol has been used in pharmacokinetic analysis and as a reference standard in fluorescence spectra analysis.
Stiripentol is an epilepsy drug, it has been used as co-therapy for treatment of epilepsy.
ChEBI: 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol is a phenylpropanoid.
